

Drug Name	Tumour Group	Regimen Name on NCCP website	Regimen Number	
5-Fluorouracil	Breast	5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy	265	
		5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy	269	
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy	381	
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy	378	
		Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy	377	
	Gastrointestinal	5-Fluorouracil (4 day) and mitoMYcin Chemoradiation Therapy	451	
		5-Fluorouracil 225mg/m2/day and Radiotherapy (RT)-Continuous infusion 7 day	421	
		Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446	
		Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449	
		CISplatin 75mg/m2 and 5-Fluorouracil Chemoradiation Therapy-Herskovic Regimen	460	
		epiRUBicin, CISplatin and 5-FU (ECF) Therapy	240	
		epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day	429	
		FLOT Therapy-14 day	344	
		FLOX Therapy	486	
		FOLFIRI (14 days)+ Cetuximab (14 days) Therapy	585	
		FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	328	
		FOLFIRI Therapy-14 day	227	
		FOLFIRINOX Therapy	329	
		FOLFOX-4 Therapy-14 day	210	
		FOLFOXIRI Therapy	555	
		Modified FOLFIRINOX Therapy	515	
		Modified FOLFOX-6 Chemoradiation Therapy-14 day	509	
		Modified FOLFOX-6 Therapy-14 day	209	
		Modified Roswell Park (Fluorouracil 500mg/m2 and Folinic Acid 50mg weekly x 6) Regimen	427	
		Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448	
		Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447	
		QUASAR (Modified) Fluorouracil(370mg/m2) and Folinic Acid (50mg) Weekly	428	
		Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days	502	
		CISplatin, Infusional 5-Fluorouracil and Radiation Therapy	594	
		Genitourinary	5-Fluorouracil and mitoMYcin Chemoradiation Therapy	450
		Head & Neck	CARBOplatini (AUC 5) and 5-Fluorouracil 1000mg/m2/day Therapy – 28 day cycle	552
			Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m2/day Therapy - 21 day cycle	418
			Cetuximab (weekly), CISplatin 100mg/m2 and 5-FU 1000mg/m2/day Therapy- 21 day cycle	417
			CISplatin and 5-Fluorouracil Therapy-28 day	314
			DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy	324

5-Fluorouracil	Head & Neck	DOCEtaxel,CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy	323	
		Noadjuvant DOCEtaxel, CISplatin, 5-Fluorouracil and Chemoradiation and Surgery	315	
Abiraterone	Genitourinary	Abiraterone 1000mg and Prednisolone 5mg Therapy	577	
Abiraterone	Genitourinary	Abiraterone and Prednisolone	103	
Afatinib	Lung	Afatinib Monotherapy	221	
Aflibercept	Gastrointestinal	Aflibercept-14 days	238	
Alectinib	Lung	Alectinib Monotherapy	401	
Anastrozole	Breast	Anastrozole Monotherapy	254	
Apalutamide	Genitourinary	Apalutamide therapy	574	
Arsenic trioxide	Leukaemia/BMT	Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy	357	
		Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy	356	
Atezolizumab	Genitourinary	Atezolizumab 1200mg Monotherapy	544	
		Atezolizumab 1680mg Monotherapy – 28 Day	593	
	Lung	Atezolizumab 1200mg Monotherapy	544	
		Atezolizumab 1680mg Monotherapy – 28 Day	593	
Avelumab	Skin/Melanoma	Avelumab Monotherapy	535	
Axitinib	Genitourinary	Axitinib Monotherapy	104	
		Pembrolizumab 200mg and Axitinib Therapy	583	
Azacitidine	Leukaemia/BMT	Azacitidine 100mg/m <sup>2</sup> 5-day Therapy	288	
		Azacitidine 75mg/m <sup>2</sup> 5-2-2 Therapy	287	
Bendamustine	Leukaemia/BMT	Bendamustine Monotherapy	527	
	Lymphoma	Brentuximab vedotin and Bendamustine Therapy	529	
		Obinutuzumab and Bendamustine Therapy-28 day cycle	424	
		riTUXimab and Bendamustine Therapy	345	
Bevacizumab	Breast	Bevacizumab 10mg/kg-14days	212	
		Bevacizumab 15mg/kg - 21 days	215	
	Gastrointestinal	Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446	
		Bevacizumab 10mg/kg-14days	212	
		Bevacizumab 15mg/kg - 21 days	215	
		Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449	
		Bevacizumab 7.5mg/kg-21days	214	
		Gemcitabine (1000mg/m <sup>2</sup> ), CARBOplatin (AUC 4) and Bevacizumab	499	
	Lung	Bevacizumab 15mg/kg - 21 days	215	
		Bevacizumab 7.5mg/kg-21days	214	
	Bicalutamide	Genitourinary	Bicalutamide Therapy	482
	binimetinib	Skin/Melanoma	Encorafenib and Binimetinib Therapy	563
	Bleomycin	Genitourinary	Bleomycin, Etoposide and CISplatin (BEP)Therapy	300
		Lymphoma	ABVD Therapy	290
Escalated Dose BEACOPP 21 day Therapy			354	
Blinatumomab	Leukaemia/BMT	Blinatumomab Therapy	538	
	Paediatric Oncology	Blinatumomab Paediatric Therapy	P00567	
Bortezomib	Myeloma	Bortezomib , Melphalan and Prednisolone	275	

Bortezomib	Myeloma	Bortezomib + Dexamethasone +Thalidomide (VTD)Induction Therapy	274		
		Bortezomib and Dexamethasone Therapy	270		
		Bortezomib Maintenance Therapy- 14 day	435		
		Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy- 21 day	416		
		Bortezomide, Cyclophosphamide and Dexamethasone -21 day Therapy	273		
		Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone –Weekly Therapy	299		
		Bosutinib	Leukaemia/BMT	Bosutinib Monotherapy	224
Brentuximab vedotin	Leukaemia/BMT	Brentuximab vedotin Monotherapy	234		
	Lymphoma	Brentuximab vedotin and Bendamustine Therapy	529		
		Brentuximab vedotin and ESHAP therapyi (BRESHAP)	530		
		Brentuximab vedotin Monotherapy	234		
Brigatinib	Lung	Brigatinib Therapy	562		
Cabazitaxel	Genitourinary	Cabazitaxel and Prednisolone	101		
Cabozantanib	Genitourinary	Cabozantanib Therapy	518		
Capecitabine	Breast	Capecitabine Monotherapy	216		
		Lapatinib and Capecitabine	217		
	Gastrointestinal	Capecitabine 825mg/m2 and RT–7 day	586		
		Capecitabine and RT – 7 day	523		
		Capecitabine and Temozolomide Therapy*	505		
		Capecitabine Monotherapy	216		
		Capecitabine/Oxaliplatin (XELOX) Therapy	321		
		CISplatin and Capecitabine Adjuvant Chemoradiation Therapy	473		
		epiRUBicin, CISplatin and Capecitabine (ECX) Therapy	380		
		epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy	239		
		Gemcitabine (1000mg/m2) and Capecitabine (830mg/m2) Therapy - 28 days	524		
		Gemcitabine + Capecitabine Therapy	384		
		CARBOplatin	Breast	CARBOplatin (AUC4-6) Monotherapy-21 days	261
				CARBOplatin (AUC4-6) Monotherapy-28 days	251
CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348				
DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days	258				
Gemcitabine and CARBOplatin (AUC2) THERAPY - 21 days	430				
CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with Radiotherapy (RT) -5 weeks	422				
Genitourinary	CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour Regimen		453		
	Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day		310		
	TICE -Autologous Conditioning Germ Cell Tumour Regimen		437		
Gynaecology	CARBOplatin (AUC 5-6) and Weekly PACLitaxel 80mg/m2 Therapy		308		
	CARBOplatin (AUC4-6) Monotherapy-21 days		261		
	CARBOplatin (AUC4-6) Monotherapy-28 days		251		

CARBOplatin	Gynaecology	CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 Therapy	303
		Gemcitabine (1000mg/m2) and CARBOplatin (AUC 4) Therapy- 21 day	306
		Gemcitabine (1000mg/m2), CARBOplatin (AUC 4) and Bevacizumab	499
	Head & Neck	CARBOplatin (AUC 2) Weekly with Radiotherapy (RT)	419
		CARBOplatin AUC (1.5) Chemoradiation Therapy-7 days	332
		CARBOplatin (AUC 5) and 5-Fluorouracil 1000mg/m2/day Therapy – 28 day cycle	552
		Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m2/day Therapy - 21 day cycle	418
	Lung	CARBOplatin (AUC 3), Etoposide (50mg/m2) and Thoracic Radiotherapy (TRT) -28 day	561
		CARBOplatin (AUC5) and Etoposide 100mg/m2 Therapy-21 day	271
		CARBOplatin (AUC6) and PACLitaxel 200mg/m2 Therapy	304
		CARBOplatin and Oral Etoposide Therapy-21 days	319
		Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day	310
		Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy	579
		Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy	568
		PEMEtrexed and CARBOplatin Therapy	318
Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m2 Therapy		309	
Lymphoma	(R**) -ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397	
carfilzomib	Myeloma	Carfilzomib (56mg/m2 once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	598
Carfilzomib		Carfilzomib, Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	405
Carmustine (BCNU)	Lymphoma	BEAM Autologous Transplant Conditioning Protocol	408
Ceritinib	Lung	Ceritinib Monotherapy	340
Cetuximab	Gastrointestinal	Cetuximab (14 days) and Irinotecan (14 days) Therapy	331
		Cetuximab (7 days) and Irinotecan (14 days) Therapy	330
		Cetuximab Monotherapy-7 days	207
		FOLFIRI (14 days)+ Cetuximab (14 days) Therapy	585
		FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	328
	Head & Neck	Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m2/day Therapy - 21 day cycle	418
		Cetuximab (weekly), CISplatin 100mg/m2 and 5-FU 1000mg/m2/day Therapy- 21 day cycle	417
Chlorambucil	Leukaemia/BMT	Chlorambucil 10mg/m2 Therapy	411
		Obinutuzumab and Chlorambucil Therapy	286
	Lymphoma	Chlorambucil 10mg/m2 Therapy	411
CISplatin	Gastrointestinal	CISplatin 75mg/m2 and 5-Fluorouracil Chemoradiation Therapy- Herskovic Regimen	460
		CISplatin and Capecitabine Adjuvant Chemoradiation Therapy	473
		CISplatin and Teysuno-28 day cycle	235
		epiRUBicin, CISplatin and 5-FU (ECF) Therapy	240
		epiRUBicin, CISplatin and Capecitabine (ECX) Therapy	380

CISplatin	Gastrointestinal	Gemcitabine (1000mg/m2) and CISplatin (25mg/m2) Therapy- 21 day	383	
		Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days	502	
		CISplatin, Infusional 5-Fluorouracil and Radiation Therapy	594	
	Genitourinary	Bleomycin, Etoposide and CISplatin (BEP)Therapy	300	
		CISplatin (40mg/m2) Weekly with Radiotherapy (RT)	385	
		CISplatin, Methotrexate and Vinblastine Therapy	337	
		Etoposide and CISplatin 20mg/m2 (EP) Therapy	301	
		Gemcitabine (1000mg/m2) and CISplatin (70mg/m2) Therapy- 28 day	282	
		Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 14 Days Therapy	333	
		Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 28 Days	338	
		Gynaecology	CISplatin (40mg/m2) Weekly with Radiotherapy (RT)	385
			Etoposide CISplatin/Etoposide Methotrexate Actinomycin D (EP/EMA) Therapy	264
	PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy		266	
	Two Day Etoposide CISplatin (EP) Therapy		267	
	Head & Neck	Cetuximab (weekly), CISplatin 100mg/m2 and 5-FU 1000mg/m2/ day Therapy- 21 day cycle	417	
		CISplatin (100mg/m2) with Radiotherapy (RT)	387	
		CISplatin (40mg/m2) Weekly with Radiotherapy (RT)	385	
		CISplatin and 5-Fluorouracil Therapy-28 day	314	
		DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy	324	
		DOCEtaxel, CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy	323	
		Gemcitabine (1250mg/m2) and CISplatin (80mg/m2) Therapy - 21 day	517	
		Neoadjuvant DOCEtaxel, CISplatin, 5-Fluorouracil and Chemoradiation and Surgery	315	
	Lung	CISplatin (50mg/m2) Etoposide (100mg/m2) and Thoracic Radiotherapy (TRT) -28 day	456	
		CISplatin (75mg/m2) + Etoposide (100mg/m2) +Thoracic Radiotherapy (TRT) -21 day	279	
		CISplatin (75mg/m2) + Etoposide Therapy-21 day	280	
		Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy- 21 day	281	
		Pembrolizumab, PEMEtrexed and CISplatin Therapy	569	
		PEMEtrexed and CISplatin Therapy	317	
		Vinorelbine and CISplatin Therapy-21 days	339	
		Vinorelbine and CISplatin Therapy-28 days	343	
		Sarcoma	(MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy	463
	DOXOrubicin (25mg/m2/day) and CISplatin (100mg/m2) Therapy - 21 day cycle		420	
	Lymphoma	(R**)- ESHAP Therapy	394	
		(R**)-DHAP Therapy	395	
		Brentuximab vedotin and ESHAP therapy (BRESHAP)	530	

CISplatin	Lymphoma	riTUXimab** Gemcitabine, Dexamethasone and CISplatin ((R**)-GDP)	441
Cladribine	Leukaemia/BMT	Cladribine 0.14mg/kg Day 1 to 5 Therapy	402
		Cladribine 0.14mg/kg Weekly Therapy	469
		Cladribine 5 day and riTUXimab Therapy	531
		Cladribine Weekly and riTUXimab Therapy	534
Cobimetinib	Skin/Melanoma	Cobimetinib and Vemurafenib Therapy	373
Crizotinib	Lung	Crizotinib Monotherapy	243
Cyclophosphamide	Breast	5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy	265
		5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy	269
		CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy	381
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy	378
		DOCEtaxel /Cyclophosphamide (TC) Therapy-21 day	250
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)	278
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)	485
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433
		DOXOrubicin and Cyclophosphamide (AC 60/600) Therapy-21 day	252
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)	260
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432
		epiRUBicin 75 + Cyclophosphamide (EC75) Therapy - 21 day	263
		epiRUBicin 90 + Cyclophosphamide (EC90) Therapy - 21 day	262
	Gynaecology	EMA/CO Therapy	248
		Leukaemia/BMT	Fludarabine, Cyclophosphamide and riTUXimab (FC IV+R) Therapy
	Lymphoma	(**riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRISTine and Prednisolone (*R)-CHOP Therapy– 14 days	409
		(*riTUXimab), Cyclophosphamide VinCRISTine and Prednisolone (*R)-CVP) Therapy– 21 days	293
		(R*)-CHOP – 21 days	307
		(R**)- miniCHOP Therapy – 21 days	436
		CHOEP Therapy– 21 days	396
		Cyclophosphamide 2000mg/m2 For Stem Cell Mobilisation	438

Cyclophosphamide	Lymphoma	Dose Adjusted R-EPOCH Therapy	355
		Escalated Dose BEACOPP 21 day Therapy	354
		Nordic Therapy	393
		Obinutuzumab and CHOP Therapy – 21 day	549
		obinutuzumab and CVP therapy -21 days	550
		R-CEOP Therapy – 21 days	510
		R-CODOX-M Therapy (Patients greater than 65 years)	403
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
		riTUXimab-HyperCVAD Therapy (MCL) – Part A	466
		Myeloma	Bortezomide, Cyclophosphamide and Dexamethasone -21 day Therapy
Modified CyBorD/ Bortezomib, Cyclophosphamide and Dexamethasone –Weekly Therapy	299		
Cyclophosphamide - Oral	Breast	Cyclophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy	377
		Leukaemia/BMT	Fludarabine, Cyclophosphamide and riTUXimab (FC Oral+R) Therapy
	Lymphoma	Dexamethasone, riTUXimab and Cyclophosphamide (DRC)Therapy	532
Cytarabine	Leukaemia/BMT	DA (50/100) (3+8) Course 2 Induction Therapy (AML-17)	360
		DA(60/100) 3+10: Course 1 Induction Therapy (AML-17)	359
		FLAG:Ida 8mg/m2 Therapy	362
		High Dose Cytarabine Therapy	365
		Intermediate Dose Cytarabine Therapy	364
	Lymphoma	(R**)- ESHAP Therapy	394
		(R**)-DHAP Therapy	395
		BEAM Autologous Transplant Conditioning Protocol	408
		Brentuximab vedotin and ESHAP therapyi (BRESHAP)	530
		High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy	508
		LEAM Autologous Transplant Conditioning Protocol	468
		Nordic Therapy	393
		riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper CVAD Part B	467
		R-IVAC Therapy (Patients greater than 65 years)	404
R-IVAC Therapy (Patients less than or equal to 65 years)	399		
Dabrafenib	Skin/Melanoma	Dabrafenib Monotherapy	237
		Trametinib and Dabrafenib Therapy	415
Dacarbazine	Sarcoma	Dacarbazine (1.2 g/m2) Therapy – 21 day	511
	Skin/Melanoma	Dacarbazine Therapy	464
	Lymphoma	ABVD Therapy	290
Dacomitinib	Lung	Dacomitinib Monotherapy	565
DACTINomycin	Gynaecology	DACTINomycin Therapy	247
		EMA/CO Therapy	248
		Etoposide CISplatin/Etoposide Methotrexate Actinomycin D (EP/EMA) Therapy	264
Daratumumab	Myeloma	Daratumumab Monotherapy	426
Daunorubicin	Leukaemia/BMT	DA (50/100) (3+8) Course 2 Induction Therapy (AML-17)	360
		DA(60/100) 3+10: Course 1 Induction Therapy (AML-17)	359

Decitabine	Leukaemia/BMT	Decitabine Monotherapy – AML (28 day cycle)	231	
Degarelix	Genitourinary	Degarelix Therapy- 28 day	481	
Dinutuximab beta	Paediatric Oncology	Dinutuximab beta and Isotretinoin Therapy	P00548	
DOCEtaxel	Breast	DOCEtaxel /Cyclophosphamide (TC) Therapy-21 day	250	
		DOCEtaxel Monotherapy 100mg/m <sup>2</sup> – 21 day cycle	202	
		DOCEtaxel Monotherapy 75mg/m <sup>2</sup> – 21 day cycle	203	
		DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days	258	
		DOXOrubicin 50mg/m <sup>2</sup> /DOCEtaxel 75mg/m <sup>2</sup> (AT 50/75) Therapy - 21 day cycle	423	
		Pertuzumab + Trastuzumab + DOCEtaxel	204	
	Gastrointestinal	DOCEtaxel Monotherapy 75mg/m <sup>2</sup> – 21 day cycle	203	
		FLOT Therapy-14 day	344	
	Genitourinary	DOCEtaxel 75mg/m <sup>2</sup> - Prednisolone combination therapy	546	
		DOCEtaxel Monotherapy 75mg/m <sup>2</sup> – 21 day cycle	203	
		DOCEtaxel Monotherapy 50mg/m <sup>2</sup> Monotherapy-14 day	313	
	Gynaecology	DOCEtaxel Monotherapy 75mg/m <sup>2</sup> – 21 day cycle	203	
	Head & Neck	DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy	324	
		DOCEtaxel, CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy	323	
		Neoadjuvant DOCEtaxel, CISplatin, 5-Fluorouracil and Chemoradiation and Surgery	315	
	Lung	DOCEtaxel Monotherapy 75mg/m <sup>2</sup> – 21 day cycle	203	
		Nindetanib Therapy	372	
	Sarcoma	Gemcitabine and DOCEtaxel Therapyi - 21 day	501	
	DOXOrubicin	Breast	CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m <sup>2</sup> followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348
			Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)	278
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)			485	
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)			316	
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)			433	
DOXOrubicin 50mg/m <sup>2</sup> /DOCEtaxel 75mg/m <sup>2</sup> (AT 50/75) Therapy - 21 day cycle			423	
DOXOrubicin and Cyclophosphamide (AC 60/600) Therapy-21 day			252	
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)			260	
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)			432	
Gastrointestinal			DOXOrubicin (60mg/m <sup>2</sup> ) Therapy	386
Genitourinary		Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 14 Days Therapy	333	



DOXOrubicin	Genitourinary	Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 28 Days	338	
		Sarcoma	(MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy	463
	DOXOrubicin (25mg/m2/day) and CISplatin (100mg/m2) Therapy - 21 day cycle		420	
	DOXOrubicin (60) and Ifosfamide Therapy		391	
	DOXOrubicin (75) and Ifosfamide Therapy		392	
	DOXOrubicin 75mg/m2 Monotherapy		500	
	Lymphoma		(**riTUXimab) Cyclophosphamide, DOXOrubicin, vinCRISTine and Prednisolone (*R)-CHOP Therapy– 14 days	409
		(R*)-CHOP – 21 days	307	
		(R**- miniCHOP Therapy – 21 days	436	
		ABVD Therapy	290	
		CHOEP Therapy– 21 days	396	
		Dose Adjusted R-EPOCH Therapy	355	
		Escalated Dose BEACOPP 21 day Therapy	354	
		Nordic Therapy	393	
		Obinutuzumab and CHOP Therapy – 21 day	549	
		R-CODOX-M Therapy (Patients greater than 65 years)	403	
R-CODOX-M Therapy (Patients less than or equal to 65 years)	398			
riTUXimab-HyperCVAD Therapy (MCL) – Part A	466			
Durvalumab	Lung	Durvalumab Monotherapy	576	
Encorafenib	Skin/Melanoma	Encorafenib and Binimetinib Therapy	563	
Enzalutamide	Genitourinary	Enzalutamide Monotherapy	233	
epiRUBicin	Breast	5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy	265	
		5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy	269	
		epiRUBicin 75 + Cyclophosphamide (EC75) Therapy - 21 day	263	
		epiRUBicin 90 + Cyclophosphamide (EC90) Therapy - 21 day	262	
	Gastrointestinal	epiRUBicin, CISplatin and 5-FU (ECF) Therapy	240	
		epiRUBicin, CISplatin and Capecitabine (ECX) Therapy	380	
		epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day	429	
epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy	239			
Eribulin	Breast	EriBULLin Monotherapy	228	
Erlotinib	Lung	Erlotinib Monotherapy	219	
Etoposide	Genitourinary	Bleomycin, Etoposide and CISplatin (BEP)Therapy	300	
		CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour Regimen	453	
		Etoposide and CISplatin 20mg/m2 (EP) Therapy	301	
		TICE -Autologous Conditioning Germ Cell Tumour Regimen	437	
		EMA/CO Therapy	248	
	Gynaecology	Etoposide CISplatin/Etoposide Methotrexate Actinomycin D (EP/EMA) Therapy	264	
		PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy	266	
		Two Day Etoposide CISplatin (EP) Therapy	267	
		Lung	CARBOplatin (AUC 3), Etoposide (50mg/m2) and Thoracic Radiotherapy (TRT) -28 day	561

Etoposide	Lung	CARBOplatin (AUC5) and Etoposide 100mg/m2 Therapy-21 day	271
		CISplatin (50mg/m2) Etoposide (100mg/m2) and Thoracic Radiotherapy (TRT) -28 day	456
		CISplatin (75mg/m2) + Etoposide (100mg/m2) +Thoracic Radiotherapy (TRT) -21 day	279
		CISplatin (75mg/m2) + Etoposide Therapy-21 day	280
		(R**)- ESHAP Therapy	394
	Lymphoma	(R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397
		BEAM Autologous Transplant Conditioning Protocol	408
		Brentuximab vedotin and ESHAP therapy (BRESHAP)	530
		CHOEP Therapy– 21 days	396
		Dose Adjusted R-EPOCH Therapy	355
		Escalated Dose BEACOPP 21 day Therapy	354
		LEAM Autologous Transplant Conditioning Protocol	468
		R-CEOP Therapy – 21 days	510
		R-IVAC Therapy (Patients greater than 65 years)	404
		R-IVAC Therapy (Patients less than or equal to 65 years)	399
		SMILE Therapy (NK or T-cell lymphoma)	407
Etoposide Oral	Lung	CARBOplatin and Oral Etoposide Therapy-21 days	319
		Oral Etoposide Therapy	388
	Lymphoma	R-CEOP Therapy – 21 days	510
Everolimus	Breast	Everolimus and Exemestane Therapy	322
	Genitourinary	Everolimus Monotherapy	320
	Neuroendocrine	Everolimus Monotherapy	320
Exemestane	Breast	Everolimus and Exemestane Therapy	322
		Exemestane Monotherapy	376
Fludarabine	Leukaemia/BMT	FLAG:Ida 8mg/m2 Therapy	362
		Fludarabine, Cyclophosphamide and riTUXimab (FC IV+R) Therapy	241
		Fludarabine, Cyclophosphamide and riTUXimab (FC Oral+R) Therapy	410
Folinic Acid	Gastrointestinal	Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446
		Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449
		FLOT Therapy-14 day	344
		FLOX Therapy	486
		FOLFIRI (14 days)+ Cetuximab (14 days) Therapy	585
		FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	328
		FOLFIRI Therapy-14 day	227
		FOLFIRINOX Therapy	329
		FOLFOX-4 Therapy-14 day	210
		FOLFOXIRI Therapy	555
		Modified FOLFIRINOX Therapy	515
		Modified FOLFOX-6 Chemoradiation Therapy-14 day	509
		Modified FOLFOX-6 Therapy-14 day	209
		Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448
		Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447
		QUASAR (Modified) Fluorouracil(370mg/m2) and Folinic Acid (50mg) Weekly	428
	Lymphoma	R-CODOX-M Therapy (Patients greater than 65 years)	403

Folinic Acid	Lymphoma	R-CODOX-M Therapy (Patients less than or equal to 65 years)	398	
		SMILE Therapy (NK or T-cell lymphoma)	407	
Fulvestrant	Breast	Fulvestrant Therapy	361	
Gefitinib	Lung	Gefitinib Monotherapy	220	
Gemcitabine	Breast	Gemcitabine and CARBOplatin (AUC2) THERAPY - 21 days	430	
		Gastrointestinal	Gemcitabine (1000mg/m2) and Capecitabine (830mg/m2) Therapy - 28 days	524
	Gemcitabine (1000mg/m2) and CISplatin (25mg/m2) Therapy- 21 day		383	
	Gemcitabine (1000mg/m2) and RT therapy		521	
	Gemcitabine (1000mg/m2) Monotherapy - 28 day		284	
	Gemcitabine (1000mg/m2) Monotherapy - 56 day		283	
	Gemcitabine (400mg/m2) and RT therapy		522	
	Gemcitabine (600mg/m2) and RT therapy		559	
	Gemcitabine + Capecitabine Therapy		384	
	Nab-PACLitaxel (Abraxane®) and Gemcitabine – 28 day		256	
	Genitourinary		Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day	310
			Gemcitabine (1000mg/m2) and CISplatin (70mg/m2) Therapy- 28 day	282
	Gynaecology	Gemcitabine (1000mg/m2) and CARBOplatin (AUC 4) Therapy- 21 day	306	
		Gemcitabine + CARBOplatin (AUC 4) Therapy-21days	306	
		Gemcitabine (1000mg/m2), CARBOplatin (AUC 4) and Bevacizumab	499	
	Head & Neck	Gemcitabine (1250mg/m2) and CISplatin (80mg/m2) Therapy - 21 day	517	
		Gemcitabine (1250mg/m2) Monotherapy - 21 day	514	
	Lung	Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day	310	
		Gemcitabine (1000mg/m2) Monotherapy - 28 day	284	
		Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy- 21 day	281	
	Sarcoma	Gemcitabine and DOCEtaxel Therapyi - 21 day	501	
	Lymphoma	R-Gemcitabine (1000mg/m2) Oxaliplatin Therapyi - 14 day	506	
		riTUXimab** Gemcitabine, Dexamethasone and CISplatin ((R**)-GDP)	441	
Goserelin	Genitourinary	Goserelin 10.8mg-12 Weekly Therapy	477	
		Goserelin 3.6mg Therapy- 4 weeks	478	
Ibrutinib	Leukaemia/BMT	Ibrutinib Therapy (CLL/ Waldenstrom's Macroglobulinaemia)	296	
	Lymphoma	Ibrutinib Therapy (Mantly Cell Lymphoma)	297	
Idarubicin	Leukaemia/BMT	FLAG:Ida 8mg/m2 Therapy	362	
		Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy	366	
Idelalisib	Leukaemia/BMT	Idelalisib and Ofatumumab Therapy	390	
		Idelalisib and riTUXimab Therapy	389	
	Lymphoma	Idelalisib Monotherapy	291	
Ifosfamide	Genitourinary	TICE -Autologous Conditioning Germ Cell Tumour Regimen	437	
	Sarcoma	DOXOrubicin (60) and Ifosfamide Therapy	391	
		DOXOrubicin (75) and Ifosfamide Therapy	392	
	Lymphoma	(R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397	

Ifosfamide	Lymphoma	R-IVAC Therapy (Patients greater than 65 years)	404
		R-IVAC Therapy (Patients less than or equal to 65 years)	399
		SMILE Therapy (NK or T-cell lymphoma)	407
Imatinib	Sarcoma	Imatinib Therpay-GIST	335
Inotuzumab ozogamicin	Leukaemia/BMT	Inotuzumab ozogamicin Monotherapy	537
Ipilimumab	Genitourinary	Nivolumab 3mg Ipilimumab 1mg Therapy	551
	Skin/Melanoma	Ipilimumab Monotherapy	105
		Nivolumab 1mg/kg Ipilimumab 3mg/kg Therapy	431
Irinotecan	Gastrointestinal	Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449
		Cetuximab (14 days) and Irinotecan (14 days) Therapy	331
		Cetuximab (7 days) and Irinotecan (14 days) Therapy	330
		FOLFIRI (14 days)+ Cetuximab (14 days) Therapy	585
		FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	328
		FOLFIRI Therapy-14 day	227
		FOLFIRINOX Therapy	329
		FOLFOXIRI Therapy	555
		Irinotecan Monotherapy - 21 days	213
		Modified FOLFIRINOX Therapy	515
		Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448
Isotretinoin	Paediatric Oncology	Dinutuximab beta and Isotretinoin Therapy	P00548
Ixazomib	Myeloma	Ixazomib, Lenalidomide and Dexamethasone Therapy - 28 day	516
Lapatinib	Breast	Lapatinib and Capecitabine	217
L-Asparaginase	Lymphoma	SMILE Therapy (NK or T-cell lymphoma)	407
Lenalidomide	Myeloma	Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy- 21 day	416
		Carfilzomib, Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	405
		Ixazomib, Lenalidomide and Dexamethasone Therapy - 28 day	516
		Lenalidomide 25mg and Dexamethasone Therapy - 28 day	218
		Carfilzomib (56mg/m <sup>2</sup> once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	598
Lenvatinib	Head & Neck	Lenvatinib -DTC Therapy	295
Letrozole	Breast	Letrozole Monotherapy	371
Leuprorelin	Genitourinary	Leuprorelin 3.75mg Therapy-28 day	494
		Leuprorelin 30mg Therapy- 24 weeks	493
		Leuprorelin 45mg Therapy- 24 week	491
		Leuprorelin 7.5mg Therapy- 28 day	490
		Leuprorelin 11.25mg Therapy- 12 weeks	492
Leuprorelin	Genitourinary	Leuprorelin 22.5mg Therapy- 12 weeks	479
Lomustine	Neuro-oncology	Procarbazine Lomustine and VinCRiStine (PCV) Therapy	379
	Lymphoma	LEAM Autologous Transplant Conditioning Protocol	468
Lorlatinib	Lung	Lorlatinib therapy	570
Melphalan	Lymphoma	BEAM Autologous Transplant Conditioning Protocol	408
		High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant	454
		LEAM Autologous Transplant Conditioning Protocol	468
	Myeloma	Bortezomib , Melphalan and Prednisolone	275

Melphalan	Myeloma	High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant	454
MESNA	Genitourinary	TICE -Autologous Conditioning Germ Cell Tumour Regimen	437
	Lymphoma	Cyclophosphamide 2000mg/m2 For Stem Cell Mobilisation SMILE Therapy (NK or T-cell lymphoma)	438 407
Methotrexate	Breast	Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy	381
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy	378
		Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy	377
	Genitourinary	CISplatin, Methotrexate and Vinblastine Therapy	337
		Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-14 Days Therapy	333
		Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-28 Days	338
	Gynaecology	EMA/CO Therapy	248
		Etoposide CISplatin/Etoposide Methotrexate Actinomycin D (EP/EMA) Therapy	264
		Intrathecal Methotrexate for CNS Prophylaxis in GTN	249
		Methotrexate 8 day Charing Cross Regimen	246
	Sarcoma	(MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy	463
		VinBLAStine and Methotrexate Therapy	554
	Lymphoma	High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy	508
		R-CODOX-M Therapy (Patients greater than 65 years)	403
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
riTUXimab-HyperCVAD Therapy (MCL) – Part A		466	
riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper CVAD Part B		467	
SMILE Therapy (NK or T-cell lymphoma)	407		
Methylprednisolone	Lymphoma	(R**) - ESHAP Therapy	394
Mifamurtide	Sarcoma	Mifamurtide	100
mitoMYcin	Gastrointestinal	5-Fluorouracil (4 day) and mitoMYcin Chemoradiation Therapy	451
	Genitourinary	5-Fluorouracil and mitoMYcin Chemoradiation Therapy	450
Nab-PACLitaxel (Abraxane®)	Breast	Nab-PACLitaxel (Abraxane) Monotherapy-21 day cycle	230
	Gastrointestinal	Nab-PACLitaxel (Abraxane®) and Gemcitabine – 28 day	256
Nindetanib	Lung	Nindetanib Therapy	372
Nivolumab	Genitourinary	Nivolumab 3mg Ipilimumab 1mg Therapy	551
		Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
	Head & Neck	Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
	Lung	Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
Skin/Melanoma	Nivolumab Monotherapy 240mg-14 day	483	

Nivolumab	Skin/Melanoma	Nivolumab Monotherapy 480mg-28day	484	
		Nivolumab 1mg/kg Ipilimumab 3mg/kg Therapy	431	
	Lymphoma	Nivolumab Monotherapy 240mg-14 day	483	
		Nivolumab Monotherapy 480mg-28day	484	
Obinutuzumab	Leukaemia/BMT	Obinutuzumab and Chlorambucil Therapy	286	
	Lymphoma	Obinutuzumab and Bendamustine Therapy-28 day cycle	424	
		Obinutuzumab and CHOP Therapy – 21 day	549	
		obinutuzumab and CVP therapy -21 days	550	
		Obinutuzumab Maintenance Therapy -56 day	425	
Ofatumumab	Leukaemia/BMT	Idelalisib and Ofatumumab Therapy	390	
Olaparib	Gynaecology	Olaparib Monotherapy	341	
Oxaliplatin	Gastrointestinal	Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446	
		Capecitabine/Oxaliplatin (XELOX) Therapy	321	
		epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day	429	
		epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy	239	
		FLOT Therapy-14 day	344	
		FLOX Therapy	486	
		FOLFIRINOX Therapy	329	
		FOLFOX-4 Therapy-14 day	210	
		FOLFOXIRI Therapy	555	
		Modified FOLFIRINOX Therapy	515	
		Modified FOLFOX-6 Chemoradiation Therapy-14 day	509	
		Modified FOLFOX-6 Therapy-14 day	209	
		Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447	
		Lymphoma	R-Gemcitabine (1000mg/m2) Oxaliplatin Therapy - 14 day	506
	PACLitaxel	Breast	CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)			278	
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)			485	
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)			316	
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)			433	
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)			260	
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)			432	
PACLitaxel (80) and Trastuzumab Therapy – 7 day (12 weeks)			512	
PACLitaxel Monotherapy 80mg/m2 7day			226	
Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle			507	
Gastrointestinal			CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with Radiotherapy (RT) -5 weeks	422
			PACLitaxel Monotherapy 80mg/m2 7day	226

PACLitaxel	Genitourinary	PACLitaxel Monotherapy 80mg/m <sup>2</sup> 7day	226
		TICE -Autologous Conditioning Germ Cell Tumour Regimen	437
	Gynaecology	CARBOplatin (AUC 5-6) and Weekly PACLitaxel 80mg/m <sup>2</sup> Therapy	308
		CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m <sup>2</sup> Therapy	303
		PACLitaxel Monotherapy 80mg/m <sup>2</sup> 7day	226
		PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy	266
	Lung	CARBOplatin (AUC6) and PACLitaxel 200mg/m <sup>2</sup> Therapy	304
		PACLitaxel Monotherapy 80mg/m <sup>2</sup> 7day	226
		Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy	579
		Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m <sup>2</sup> Therapy	309
Palbociclib	Breast	Palbociclib Therapy-28 day	414
Panitumumab	Gastrointestinal	Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448
		Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447
		Panitumumab 6mg/kg Therapy	225
Pazopanib	Genitourinary	Pazopanib Therapy	445
	Sarcoma	Pazopanib Therapy	445
Pegylated Liposomal DOXOrubicin (CAELYX)	Breast	Pegylated Liposomal DOXOrubicin 50mg/m <sup>2</sup> (CAELYX) <sup>®</sup> 28 days	205
	Gynaecology	Pegylated Liposomal DOXOrubicin 50mg/m <sup>2</sup> (CAELYX) <sup>®</sup> 28 days	205
		Trabectedin and Pegylated Liposomal DOXOrubicin(PLD) Therapy	375
Sarcoma	Pegylated Liposomal DOXOrubicin 20mg/m <sup>2</sup> (CAELYX) <sup>®</sup> 21 days	462	
Pembrolizumab	Genitourinary	Pembrolizumab 200mg Monotherapy	455
		Pembrolizumab 400mg Monotherapy	558
		Pembrolizumab 200mg and Axitinib Therapy	583
	Lung	Pembrolizumab 200mg Monotherapy	455
		Pembrolizumab 400mg Monotherapy	558
		Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy	579
		Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy	568
		Pembrolizumab, PEMEtrexed and CISplatin Therapy	569
	Skin/Melanoma	Pembrolizumab 200mg Monotherapy	455
		Pembrolizumab 2mg/kg Therapy	347
		Pembrolizumab 400mg Monotherapy	558
	Lymphoma	Pembrolizumab 200mg Monotherapy	455
		Pembrolizumab 400mg Monotherapy	558
PEMEtrexed	Lung	Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy	568
		Pembrolizumab, PEMEtrexed and CISplatin Therapy	569
		PEMEtrexed and CARBOplatin Therapy	318
		PEMEtrexed and CISplatin Therapy	317
		PEMEtrexed Monotherapy	222
Pertuzumab	Breast	Pertuzumab + Trastuzumab + DOCEtaxel	204
		pertuzumab and trastuzumab and chemotherapy -21 day cycles	350
		Pertuzumab Trastuzumab and VinORELBine	526
		Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle	507
Pixantrone	Lymphoma	Pixantrone Therapy	255
Plerixafor	Leukaemia/BMT	Plerixafor and G-CSF Therapy	536

Pomalidomide	Myeloma	Pomalidomide and Dexamethasone	245	
Ponatinib	Leukaemia/BMT	Ponatinib Therapy	302	
Procarbazine	Neuro-oncology	Procarbazine Lomustine and VinCRISTine (PCV) Therapy	379	
	Lymphoma	Escalated Dose BEACOPP 21 day Therapy	354	
Radium 223	Genitourinary	Radium 223 Therapy	257	
Regorafenib	Gastrointestinal	Regorafenib Monotherapy	244	
Ribociclib	Breast	Ribociclib Therapy-28 day	525	
riTUXimab	Leukaemia/BMT	Cladribine 5 day and riTUXimab Therapy	531	
		Cladribine Weekly and riTUXimab Therapy	534	
		Fludarabine, Cyclophosphamide and riTUXimab (FC IV+R) Therapy	241	
	Lymphoma	Fludarabine, Cyclophosphamide and riTUXimab (FC Oral+R) Therapy	410	
		Idelalisib and riTUXimab Therapy	389	
		(**riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRISTine and Prednisolone (*R)-CHOP Therapy– 14 days	409	
		(*riTUXimab), Cyclophosphamide VinCRISTine and Prednisolone (*R)-CVP) Therapy– 21 days	293	
		(R*)-CHOP – 21 days	307	
		(R**)- ESHAP Therapy	394	
		(R**)- miniCHOP Therapy – 21 days	436	
		(R**)-DHAP Therapy	395	
		(R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397	
		Dexamethasone, riTUXimab and Cyclophosphamide (DRC)Therapy	532	
		Dose Adjusted R-EPOCH Therapy	355	
		High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy	508	
		Nordic Therapy	393	
		R-CEOP Therapy – 21 days	510	
		R-CODOX-M Therapy (Patients greater than 65 years)	403	
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398	
		R-Gemcitabine (1000mg/m2) Oxaliplatin Therapyi - 14 day	506	
		riTUXimab 375 mg/m2 Combination Therapy-21 day	542	
		RiTUXimab 375 mg/m2 Maintenance Therapy- 56 day	543	
		RiTUXimab 375 mg/m2 Maintenance Therapy-84 day	540	
		RiTUXimab 375 mg/m2 Therapy-7 day	541	
		riTUXimab and Bendamustine Therapy	345	
		riTUXimab** Gemcitabine, Dexamethasone and CISplatin ((R**)-GDP)	441	
		riTUXimab-HyperCVAD Therapy (MCL) – Part A	466	
		riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper CVAD Part B	467	
		R-IVAC Therapy (Patients greater than 65 years)	404	
		R-IVAC Therapy (Patients less than or equal to 65 years)	399	
	Ruxolitinib	Leukaemia/BMT	Ruxolitinib Monotherapy	229
	Siltuximab	Lymphoma	Siltuximab Monotherapy	277
	Sorafenib	Gastrointestinal	Sorafenib Therapy	294



Sorafenib	Genitourinary	Sorafenib Therapy	294
	Head & Neck	Sorafenib Therapy	294
Sunitinib	Genitourinary	Sunitinib 50mg Therapy	325
	Sarcoma	Sunitinib 50mg Therapy	325
	Neuroendocrine	Sunitinib 37.5mg Therapy	327
Tamoxifen	Breast	Tamoxifen Monotherapy	253
Temozolomide	Gastrointestinal	Capecitabine and Temozolomide Therapy*	505
	Neuro-oncology	Temozolomide Recurrent Therapy	342
		Temozolomide with Radiotherapy (RT) and Adjuvant Therapy- Patients greater than 65 years	461
		Temozolomide with RT and Adjuvant Therapy	334
Temsirolimus	Genitourinary	Temsirolimus Monotherapy	326
Teysuno	Gastrointestinal	CISplatin and Teysuno-28 day cycle	235
Thalidomide	Myeloma	Bortezomib + Dexamethasone +Thalidomide (VTD)Induction Therapy	274
Thiotepa	Lymphoma	High dose Methotrexate, high dose cytarabine, ritUXimab and thiotepa (MATRix) therapy	508
Tipracil	Gastrointestinal	Trifluridine and Tipiracil (Lonsurf®) Therapy	382
Tivozanib	Genitourinary	Tivozanib Therapy	564
Topotecan	Gynaecology	Topotecan Monotherapy-5 day	311
		Topotecan Monotherapy-Weekly	312
	Lung	Topotecan Monotherapy-5 day	311
		Topotecan Oral Monotherapy	587
Trabectedin	Gynaecology	Trabectedin and Pegylated Liposomal DOXOrubicin(PLD) Therapy	375
	Sarcoma	Trabectedin Monotherapy	374
Trametinib	Skin/Melanoma	Trametinib and Dabrafenib Therapy	415
Trastuzumab Emtansine (Kadcyla®)	Breast	Trastuzumab Emtansine (Kadcyla®) - 21 days	206
Trastuzumab IV	Breast	Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432
		PACLitaxel (80) and Trastuzumab Therapy – 7 day (12 weeks)	512
		Pertuzumab + Trastuzumab + DOCEtaxel	204
		pertuzumab and trastuzumab and chemotherapy -21 day cycles	350
		Pertuzumab Trastuzumab and VinORELBine	526
		Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle	507
		Trastuzumab (IV) Monotherapy 21 days	200
		Trastuzumab (IV) Monotherapy 7 days	201
	Gastrointestinal	Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days	502
Trastuzumab SC	Breast	Trastuzumab SC 21 days-Early Breast Cancer	285

Trastuzumab SC	Breast	Trastuzumab Subcutaneous 21 days- Metastatic Breast Carcinoma	272
Trastuzumab	Breast	DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days	258
Tretinoin (ATRA)	Leukaemia/BMT	Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy	357
		Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy	356
		Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy	366
Trifluridine	Gastrointestinal	Trifluridine and Tipiracil (Lonsurf®) Therapy	382
Triptorelin	Genitourinary	Triptorelin 11.25mg Therapy- 12 weeks	480
		Triptorelin 22.6mg Therapy- 24 weeks	488
		Triptorelin 3mg Therapy- 28 day	489
Vandetanib	Head & Neck	Vandetanib Monotherapy	242
Vemurafenib	Skin/Melanoma	Cobimetinib and Vemurafenib Therapy	373
		Vemurafenib Monotherapy	102
Venetoclax	Leukaemia/BMT	Venetoclax Monotherapy	400
Vinblastine	Genitourinary	CISplatin, Methotrexate and Vinblastine Therapy	337
		Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 14 Days Therapy	333
		Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 28 Days	338
	Sarcoma	VinBLASTine and Methotrexate Therapy	554
	Lymphoma	ABVD Therapy	290
Vincristine	Gynaecology	EMA/CO Therapy	248
	Neuro-oncology	Procarbazine Lomustine and VinCRISTine (PCV) Therapy	379
	Lymphoma	(**riTUXimab) Cyclophosphamide, DOXOrubicin, vinCRISTine and Prednisolone (*R)-CHOP Therapy– 14 days	409
		(*riTUXimab), Cyclophosphamide VinCRISTine and Prednisolone (*R)-CVP) Therapy– 21 days	293
		(R*)-CHOP – 21 days	307
		(R**)- miniCHOP Therapy – 21 days	436
		CHOEP Therapy– 21 days	396
		Dose Adjusted R-EPOCH Therapy	355
		Escalated Dose BEACOPP 21 day Therapy	354
		Nordic Therapy	393
		Obinutuzumab and CHOP Therapy – 21 day	549
		obinutuzumab and CVP therapy -21 days	550
		R-CEOP Therapy – 21 days	510
		R-CODOX-M Therapy (Patients greater than 65 years)	403
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
riTUXimab-HyperCVAD Therapy (MCL) – Part A	466		
Vinorelbine IV	Breast	Intravenous Vinorelbine Monotherapy-21day	232
		Pertuzumab Trastuzumab and VinORELBine	526
	Gynaecology	Intravenous Vinorelbine Monotherapy-21day	232
	Lung	Intravenous Vinorelbine Monotherapy-21day	232
		Vinorelbine and CISplatin Therapy-21 days	339
		Vinorelbine and CISplatin Therapy-28 days	343
Vinorelbine Oral	Breast	Oral Vinorelbine Monotherapy-7days	259
	Lung	Oral Vinorelbine Monotherapy-7days	259
Vismodegib	Skin/Melanoma	Vismodegib Monotherapy	236
Zoledronic acid	Breast	Zoledronic acid monotherapy	545